hepsulfam has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geller, RB; Grochow, LB; Janisch, L; Larson, RA; Milton, J; Ratain, MJ | 1 |
| Adlakha, A; Cook, CA; Furmanski, P; Gibson, NW; Hincks, JR; Johnson, CS | 1 |
1 trial(s) available for hepsulfam and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Brain Diseases; Coma; Dose-Response Relationship, Drug; Electroencephalography; Female; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sulfonic Acids; Thrombocytopenia | 1995 |
1 other study(ies) available for hepsulfam and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; Busulfan; Cell Survival; Colony-Forming Units Assay; DNA Damage; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sulfonic Acids | 1990 |